BioNTech co-founders Uğur Şahin and Özlem Türeci (Sebastian Gollnow/picture-alliance/dpa/AP Images)

Pfiz­er and BioN­Tech file BLA for Omi­cron-tar­get­ing Covid-19 vac­cine

Pfiz­er and BioN­Tech are seek­ing full ap­proval for their Omi­cron-tar­get­ed bi­va­lent Covid shot, and they’re fol­low­ing an FDA ad­vi­so­ry com­mit­tee’s ad­vice on “har­mo­niz­ing” vac­cine com­po­si­tions.

The part­ners have filed a sup­ple­men­tal BLA for their Omi­cron BA.4/BA.5-adapt­ed bi­va­lent Covid-19 vac­cine as both a pri­ma­ry dose or a boost­er for pa­tients over the age of 12. That means un­vac­ci­nat­ed chil­dren and adults could skip the orig­i­nal pri­ma­ry se­ries and re­ceive a bi­va­lent shot first.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.